The Food and Drug Administration'sCenter for Devices and Radiological Health will discuss the classificationof PACS devices at a hearing to be held Aug. 29. The hearing willbe conducted by the Medical Devices Advisory Committee's radiologicaldevices
The Food and Drug Administration'sCenter for Devices and Radiological Health will discuss the classificationof PACS devices at a hearing to be held Aug. 29. The hearing willbe conducted by the Medical Devices Advisory Committee's radiologicaldevices panel.
PACS devices do not have their own classification and insteadare categorized as radiology accessories for purposes of governmentregulation. The rapid growth of PACS suggests that the devicesbe given their own classification, according to Robert Phillipsof the CDRH.
The panel will also discuss minor changes to PACS regulation.For example, the FDA may ease off on requirements that storageand communication devices receive 510(k) clearance before theycan be marketed, Phillips said.
The FDA is seeking industry participation in the hearing, whichwill be held at 2:30 p.m. in Room G of the Parklawn building atthe FDA's headquarters at 5600 Fishers Lane in Rockville, MD.For more information call Phillips at 301/594-1212.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.